All In Biotech

Drug Trial Radar · NCT07227350

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms of the study and will receive intralesional injections of: (i) Monotherapy 13 Mio IU (\~2.17 mg) L19IL2; or (ii) Monotherapy 0.4 mg L19TNF; or (iii) Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF, once weekly for 4 consecutive weeks. Patients will be followed for a maximum of 156 weeks after beginning of treatment.

Conditions

  • Locally Advanced Basal Cell Carcinoma

Interventions

  • L19IL2Drug

    Intratumoral injections

  • L19TNFDrug

    Intratumoral injections

  • L19IL2/L19TNFDrug

    Intratumoral injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response RateTime frame: from enrollment to week 16

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Not yet recruiting

  • The Ohio State University Wexner Medical Center Clinical Laboratories

    Columbus, Ohio · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Universitaetsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • Charite Universitaetsmedizin Berlin KöR

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Essen AöR

    Essen, Germany · Recruiting

  • Universitaetsklinikum Halle (Saale) AöR

    Halle, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein AöR

    Kiel, Germany · Recruiting

  • Universitaetsklinikum Tuebingen AöR

    Tübingen, Germany · Recruiting

  • Andreas Syngros Hospital Of Venereal And Dermatological Diseases

    Athens, Greece · Not yet recruiting

  • IRCCS Istituto Nazionale Tumori Fondazione Pascale

    Naples, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Humanitas Mirasole S.p.A.

    Rozzano, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Senese

    Siena, Italy · Recruiting

  • Hospital Clinic De Barcelona

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.